Schematic illustration of comprehensive and combination RA therapy by Ce-MSCNV nanoparticles. Ce-MSCNVs scavenge the over-produced ROS in an RA knee joint, induce M1 to M2 macrophage polarization for immediate relief of inflammation and symptoms, modulate DCs into tDCs, and finally induce Tregs.
CREDIT: Institute for Basic Science
Ceria nanoparticle-immobilized mesenchymal stem cell nanovesicle hybrid system offers both immediate pain relief and long-term immune tolerance
A team of scientists led by KOO Sagang from the Seoul National University and Center for Nanoparticle Research within the Institue for Basic Science Center (IBS), in collaboration with researchers from Korea Institute of Science and Technology (KIST) and the Seoul National University, developed a new solution for the treatment of rheumatoid arthritis (RA).
RA is a chronic disease that, unfortunately, has no cure. The disease triggers a mix of troublesome symptoms like inflamed joints, harmful cytokines, and immune system imbalances, which work together to create a relentless cycle of worsening symptoms. While targeting some of these factors can provide short-term relief, others remain unresolved, leading to a frustrating cycle of remission and flare-ups.
One of the major hurdles in RA treatment is the inability to restore the immune system to its healthy state. This leaves the body unable to control the continuous production of harmful substances like reactive oxygen species (ROS) and inflammatory cytokines, leading to persistent inflammation and discomfort.
In essence, the ideal treatment for RA should not only provide immediate relief from inflammation and symptoms but also address the root cause by restoring the immune system to its normal, balanced state.
New nanoparticle-based system as a solution
The new platform involves immobilizing ceria nanoparticles (Ce NPs) onto mesenchymal stem cell-derived nanovesicles (MSCNVs). Both of these components can hinder different pathogenic factors, allowing them to work both individually and cooperatively to achieve a comprehensive treatment.
Ce NPs – can scavenge the overproduced ROS in RA-inflicted knee joints. They also induce polarization of M1 macrophages into M2, achieving immediate relief of inflammation and symptoms.
MSCNVs – deliver immunomodulatory cytokines, which turn dendritic cells (DC) into tolerogenic dendritic cells (tDCs). This consequently generates regulatory T cells for long-term immune tolerance.
In short, this approach aims to bridge both innate and adaptive immunity to achieve both short-term pain relief, as well as convert the tissue environment into an immune-tolerant state to prevent the recurrence of symptoms.
Researchers confirmed the efficacy of this approach using a collagen-induced arthritis mouse model. The Ce-MSCNV system was able to comprehensively treat and prevent RA by simultaneously relieving the immediate and restoring T cell immunity. Supporting data suggest that improvement in conditions can be achieved after only a single-dose treatment.
The mice treated with the Ce-MSCNV combination fared far better compared to the ones only treated using the Ce NP or MSCNV group. This clearly demonstrates the synergy between anti-inflammation and immunomodulation and underlines the importance of the combined therapy for effective RA treatment. In addition, Ce-MSCNV administration prior to booster injection markedly reduced the incidence and severity of symptoms, supporting the prophylactic potential of these nanoparticles.
First author KOO Sagang stated, “One of the hardest decisions in intractable disease therapy is determining how long the treatment should be carried on. For RA, it would not be appropriate to stop treatment just because the target marker is stabilized. A safer indicator should be that the innate and adaptive components of the collapsed immune system are normalized to protect the body.”
Koo believes that the strategy adopted by Ce-MSCNVs, where different treatment mechanisms work together, provides a unique advantage in this regard. Furthermore, she predicts that a similar approach would also be applicable to other intractable, inflammatory, and autoimmune diseases for this purpose. The components within the system may also be modified. For example, other catalysts for generating ROS or other cell-derived nanovesicles could be utilized depending on the types of diseases. Overall, this study proves the potential of a hybrid nanoparticle system for the comprehensive treatment of autoimmune disease and modulation of the immune system.
Original Article: New nanoparticles found to be effective for the treatment of rheumatoid arthritis
More from: Seoul National University | Korea Institute of Science and Technology | The Institute for Basic Science
The Latest Updates from Bing News
Go deeper with Bing News on:
Rheumatoid arthritis treatment
- Does extreme heat aggravate arthritis? know from doctor
Arthritis, a condition characterized by inflammation of the joints, affects millions of people worldwide. There are various types of arthrit..|News Track ...
- AbbVie Stock Falls As Company Warns of Continued Humira Sales Slump
AbbVie warned Friday that sales of its blockbuster arthritis drug, Humira, will continue to lose market share to biosimilars.
- AbbVie looks to Skyrizi, other drugs to replace blockbuster Humira sales
AbbVie Inc. plans to lean financially on increasing sales for several drugs in its stable, such as its Skyrizi medicine, to counter the decline in sales of Humira, as other manufacturers now are ...
- Biogen's Tofidence Gets Positive CHMP Opinion For Rheumatoid Arthritis,Juvenile Arthritis & COVID-19
Biogen Inc. (BIIB) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA ...
- Arthritis linked to blood cancer mutations
A team of Adelaide and U.S. researchers has discovered a link between a less common form of rheumatoid arthritis and gene mutations found in blood cancer.
Go deeper with Bing News on:
Ce-MSCNV system
- Industry vets launch new mortgage CE company, MLO Force
Nathan Knottingham announced the launch of a new mortgage CE provider, MLO Force, from the stage at HousingWire's The Gathering this week.
- Front Line Medical Technologies achieves CE marking for transforming aortic occlusion
In a remarkable development, Front Line Medical Technologies Inc., an innovator in trauma care medical devices, has announced the attainment of CE marking for its COBRA-OS (Control of Bleeding, ...
- NEC and MIPS Technologies Announce Windows CE Operating System Support for 64-Bit Microprocessors
The Microsoft Windows CE operating system, which includes the Platform Builder comprehensive toolkit for building Windows CE-based OS images, offers a compelling platform for creating high-performance ...
- Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System
Axonics, Inc. AXNX recently achieved a milestone with the CE Mark approval of its fourth-generation rechargeable Sacral Neuromodulation (SNM) system, the R20. This groundbreaking device is set to ...
- Continuing Education
This is a policy change implemented in 2021. There is currently no cost to become a continuing education provider for the CEP Institute. Approved providers receive log-in credentials to the CEPI ...